TY - JOUR
T1 - Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands
AU - Westgeest, Hans M.
AU - Kuppen, Malou C. P.
AU - van den Eertwegh, Alphonsus J. M.
AU - de Wit, Ronald
AU - Coenen, Juleon L. L. M.
AU - van den Berg, H. P. (Pieter)
AU - Mehra, Niven
AU - van Oort, Inge M.
AU - Fossion, Laurent M. C. L.
AU - Hendriks, Mathijs P.
AU - Bloemendal, Haiko J.
AU - van de Luijtgaarden, Addy C. M.
AU - ten Bokkel Huinink, Daan
AU - van den Bergh, A. C. M. (Fons)
AU - van den Bosch, Joan
AU - Polee, Marco B.
AU - Weijl, Nir
AU - Bergman, Andre M.
AU - Uyl-de Groot, Carin A.
AU - Gerritsen, Winald R.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.
AB - In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070706340&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31439536
U2 - 10.1016/j.clgc.2019.05.018
DO - 10.1016/j.clgc.2019.05.018
M3 - Article
C2 - 31439536
VL - 17
SP - e946-e956
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
SN - 1558-7673
IS - 5
ER -